Presentation is loading. Please wait.

Presentation is loading. Please wait.

Baseline characteristics of the participants according to study group.

Published byMehmed Ekici Modified over 5 years ago

Similar presentations

Presentation on theme: "Baseline characteristics of the participants according to study group."— Presentation transcript:

1 Baseline characteristics of the participants according to study group.
Baseline characteristics of the participants according to study group. The absolute values at baseline (T0) for TNF-α and IL-6, CRP, BAP test, and IGF-1 was graphically represented by means of box-plots. Quantitative variables were summarized using percentiles (median and IQR). p Value by Wilcoxon rank-sum test are referred to differences between the two treatment groups. CRP, C reactive protein; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; BAP test, biological antioxidant potential of plasma test; IGF-1, insulin-like growth factor-1. Andreea Soare et al. BMJ Open Diab Res Care 2015;3:e000079 ©2015 by American Diabetes Association

Download ppt "Baseline characteristics of the participants according to study group."

Similar presentations

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type  2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.

Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type  2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.
Differences in the glycated hemoglobin (HbA1c) levels.

Differences in the glycated hemoglobin (HbA1c) levels.
OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.

OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.
Pg and Ec LPS induced levels of soluble mediators from in cultures of individuals with and without T2D with periodontitis. Pg and Ec LPS induced levels.

Pg and Ec LPS induced levels of soluble mediators from in cultures of individuals with and without T2D with periodontitis. Pg and Ec LPS induced levels.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
Effect of Ma-Pi diet versus control diet on change in TNF-α, IL-6, CRP, BAP test, and IGF-1. Effect of Ma-Pi diet versus control diet on change in TNF-α,

Effect of Ma-Pi diet versus control diet on change in TNF-α, IL-6, CRP, BAP test, and IGF-1. Effect of Ma-Pi diet versus control diet on change in TNF-α,
OR (95% CI) for CHD associated with inflammatory markers in all participants and in subsets of non-users of statins or non-users of aspirin therapy. OR.

OR (95% CI) for CHD associated with inflammatory markers in all participants and in subsets of non-users of statins or non-users of aspirin therapy. OR.
Box plot representing the median GIRs (mg/kg/min) by CD300LG genotype during the last 30 min of the HEC. The center lines show the medians; box limits.

Box plot representing the median GIRs (mg/kg/min) by CD300LG genotype during the last 30 min of the HEC. The center lines show the medians; box limits.
(A–B) Box plot representing the median relative expression of CD300LG mRNA in skeletal muscle (A) and in SAT (B) by CD300LG genotype. (A–B) Box plot representing.

(A–B) Box plot representing the median relative expression of CD300LG mRNA in skeletal muscle (A) and in SAT (B) by CD300LG genotype. (A–B) Box plot representing.
Serum levels of angiopoietin-like protein 4 according to (A) cardiac dysfunction (ie, abnormal N-terminal pro-B-type natriuretic peptide level) and (B)

Serum levels of angiopoietin-like protein 4 according to (A) cardiac dysfunction (ie, abnormal N-terminal pro-B-type natriuretic peptide level) and (B)
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
Unstimulated levels of soluble mediators from in cultures of individuals with and without T2D with periodontitis. Unstimulated levels of soluble mediators.

Unstimulated levels of soluble mediators from in cultures of individuals with and without T2D with periodontitis. Unstimulated levels of soluble mediators.
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.
Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Similar presentations

Ads by Google